Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vanutide cridificar in patients with mild to moderate Alzheimer's disease

Trial Profile

Vanutide cridificar in patients with mild to moderate Alzheimer's disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2010

At a glance

  • Drugs Vanutide cridificar (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Elan Pharmaceuticals
  • Most Recent Events

    • 24 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top